DNLI
Price
$21.46
Change
-$0.03 (-0.14%)
Updated
Dec 20, 04:59 PM (EDT)
71 days until earnings call
FOLD
Price
$9.80
Change
+$0.07 (+0.72%)
Updated
Dec 20 closing price
66 days until earnings call
Ad is loading...

DNLI vs FOLD

Header iconDNLI vs FOLD Comparison
Open Charts DNLI vs FOLDBanner chart's image
Denali Therapeutics
Price$21.46
Change-$0.03 (-0.14%)
Volume$23.05K
CapitalizationN/A
Amicus Therapeutics
Price$9.80
Change+$0.07 (+0.72%)
Volume$4.08M
CapitalizationN/A
DNLI vs FOLD Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. FOLD commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and FOLD is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (DNLI: $21.45 vs. FOLD: $9.80)
Brand notoriety: DNLI and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 320% vs. FOLD: 146%
Market capitalization -- DNLI: $3.09B vs. FOLD: $2.93B
DNLI [@Biotechnology] is valued at $3.09B. FOLD’s [@Biotechnology] market capitalization is $2.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while FOLD’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 6 bearish.
  • FOLD’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -6.62% price change this week, while FOLD (@Biotechnology) price change was +4.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 03, 2025.

FOLD is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.09B) has a higher market cap than FOLD($2.93B). DNLI YTD gains are higher at: -0.047 vs. FOLD (-30.937). FOLD has higher annual earnings (EBITDA): -9.2M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. FOLD (250M). DNLI has less debt than FOLD: DNLI (52.5M) vs FOLD (445M). FOLD has higher revenues than DNLI: FOLD (494M) vs DNLI (0).
DNLIFOLDDNLI / FOLD
Capitalization3.09B2.93B105%
EBITDA-496.05M-9.2M5,395%
Gain YTD-0.047-30.9370%
P/E RatioN/AN/A-
Revenue0494M-
Total Cash837M250M335%
Total Debt52.5M445M12%
FUNDAMENTALS RATINGS
DNLI vs FOLD: Fundamental Ratings
DNLI
FOLD
OUTLOOK RATING
1..100
5550
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8060
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (75) in the Biotechnology industry is in the same range as DNLI (94). This means that FOLD’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as FOLD (100). This means that DNLI’s stock grew similarly to FOLD’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as FOLD (98). This means that DNLI’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Price Growth Rating (60) in the Biotechnology industry is in the same range as DNLI (80). This means that FOLD’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as FOLD (100). This means that DNLI’s stock grew similarly to FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIFOLD
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
70%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 14 days ago
79%
Bullish Trend 3 days ago
74%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 5 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
77%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWCIX28.440.35
+1.25%
Hotchkis & Wiley Disciplined Value I
VSEMX235.112.90
+1.25%
Vanguard Extended Market Index Instl Sel
JOEMX11.480.05
+0.44%
JOHCM Emerging Markets Opps Instl
IHORX18.79-0.02
-0.11%
Hartford International Opportunities R3
GQJIX9.83-0.10
-1.01%
GQG Partners Intl Qual Val Fd Ins

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.19%
BEAM - DNLI
64%
Loosely correlated
+8.04%
JANX - DNLI
55%
Loosely correlated
+0.14%
NTLA - DNLI
55%
Loosely correlated
+0.83%
LGND - DNLI
54%
Loosely correlated
+0.61%
CRSP - DNLI
53%
Loosely correlated
+0.83%
More